{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:02:35Z","timestamp":1789549355411,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82201930"],"award-info":[{"award-number":["82201930"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371802"],"award-info":[{"award-number":["82371802"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2025J011438"],"award-info":[{"award-number":["2025J011438"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010166","name":"Xiamen Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","award":["3502Z20244ZD1025"],"award-info":[{"award-number":["3502Z20244ZD1025"]}],"id":[{"id":"10.13039\/100010166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10067-026-08317-2","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T10:31:31Z","timestamp":1786098691000},"page":"6199-6211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of baseline anti-Ro52 seropositivity with connective tissue disease development following interferon-\u03b1 therapy in patients with chronic hepatitis B"],"prefix":"10.1007","volume":"45","author":[{"given":"Yongxin","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqiong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiulan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixiu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6456-0363","authenticated-orcid":false,"given":"Yuechi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"10161","key":"8317_CR1","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","volume":"392","author":"WK Seto","year":"2018","unstructured":"Seto WK, Lo YR, Pawlotsky JM, Yuen MF (2018) Chronic hepatitis B virus infection. Lancet 392(10161):2313\u20132324. https:\/\/doi.org\/10.1016\/S0140-6736(18)31865-8","journal-title":"Lancet"},{"issue":"11","key":"8317_CR2","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","volume":"18","author":"GC Fanning","year":"2019","unstructured":"Fanning GC, Zoulim F, Hou J, Bertoletti A (2019) Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov 18(11):827\u2013844. https:\/\/doi.org\/10.1038\/s41573-019-0037-0","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"8317_CR3","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1136\/gutjnl-2024-332290","volume":"73","author":"A Vecchi","year":"2024","unstructured":"Vecchi A, Rossi M, Tiezzi C, Fisicaro P, Doselli S, Gabor EA, Penna A, Montali I, Ceccatelli Berti C, Reverberi V, Montali A, Fletcher SP, Degasperi E, Sambarino D, Laccabue D, Facchetti F, Schivazappa S, Loggi E, Coco B, Cavallone D, Rosselli Del Turco R, Massari M, Pedrazzi G, Missale G, Verucchi G, Andreone P, Brunetto MR, Lampertico P, Ferrari C, Boni C (2024) HBcrAg values may predict virological and immunological responses to pegIFN-\u03b1 in NUC-suppressed HBeAg-negative chronic hepatitis B. Gut 73(10):1737. https:\/\/doi.org\/10.1136\/gutjnl-2024-332290","journal-title":"Gut"},{"issue":"22","key":"8317_CR4","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1056\/NEJMoa2405485","volume":"391","author":"J Hou","year":"2024","unstructured":"Hou J, Zhang W, Xie Q, Hua R, Tang H, Morano Amado LE, Yang SS, Peng CY, Su WW, Chuang WL, Kim DJ, Avihingsanon A, Kao JH, Leerapun A, Yuen MF, Asselah T, Liang X, Bo Q, Canducci F, Catanese MT, Chen E, Cheng C, Chughlay F, Das S, Glavini K, Guerreiro N, Huang Y, Kakrana P, Kazma R, Patil A, Pavlovic V, Surujbally B, Triyatni M, Upmanyu R, Wat C, Gane E, Piranga Study G (2024) Xalnesiran with or without an immunomodulator in chronic hepatitis B. N Engl J Med 391(22):2098\u20132109. https:\/\/doi.org\/10.1056\/NEJMoa2405485","journal-title":"N Engl J Med"},{"key":"8317_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev-pathol-020117-043952","volume":"14","author":"MK Crow","year":"2019","unstructured":"Crow MK, Olferiev M, Kirou KA (2019) Type I interferons in autoimmune disease. Annu Rev Pathol 14:369\u2013393. https:\/\/doi.org\/10.1146\/annurev-pathol-020117-043952","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"8317_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/rai2.12125","volume":"4","author":"M Chang","year":"2024","unstructured":"Chang M, Yao K, Hao J, Long Y, Qiao L, Zhang Y, Ma K, He P (2024) Assessing the causality of interferon-\u03b3 and its receptor 1\/2 with systemic lupus erythematosus risk using genetic data. Rheumatology & Autoimmunity 4(2):109\u2013118. https:\/\/doi.org\/10.1002\/rai2.12125","journal-title":"Rheumatology & Autoimmunity"},{"issue":"2","key":"8317_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"EASL","year":"2017","unstructured":"EASL (2017) clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 67(2):370\u2013398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021","journal-title":"J Hepatol"},{"issue":"3","key":"8317_CR8","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/hep.510240309","volume":"24","author":"GV Gregorio","year":"1996","unstructured":"Gregorio GV, Jones H, Choudhuri K, Vegnente A, Bortolotti F, Mieli-Vergani G, Vergani D (1996) Autoantibody prevalence in chronic hepatitis B virus infection: effect in interferon alfa. Hepatology 24(3):520\u2013523. https:\/\/doi.org\/10.1002\/hep.510240309","journal-title":"Hepatology"},{"issue":"1","key":"8317_CR9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3748\/wjg.v21.i1.283","volume":"21","author":"BA Li","year":"2015","unstructured":"Li BA, Liu J, Hou J, Tang J, Zhang J, Xu J, Song YJ, Liu AX, Zhao J, Guo JX, Chen L, Wang H, Yang LH, Lu J, Mao YL (2015) Autoantibodies in Chinese patients with chronic hepatitis B: prevalence and clinical associations. World J Gastroenterol 21(1):283\u2013291. https:\/\/doi.org\/10.3748\/wjg.v21.i1.283","journal-title":"World J Gastroenterol"},{"issue":"3","key":"8317_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.103013","volume":"21","author":"P Decker","year":"2022","unstructured":"Decker P, Moulinet T, Pontille F, Cravat M, De Carvalho Bittencourt M, Jaussaud R (2022) An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management. Autoimmun Rev 21(3):103013. https:\/\/doi.org\/10.1016\/j.autrev.2021.103013","journal-title":"Autoimmun Rev"},{"key":"8317_CR11","unstructured":"Wodkowski M, Hudson M, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Wang M, Baron M, Fritzler MJ; Canadian Scleroderma Research G; Australian Scleroderma Cohort S; Genetics versus Environment in Scleroderma Outcome S (2015) Monospecific anti-Ro52\/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. Clin Exp Rheumatol 33(4 Suppl 91):S131-135"},{"issue":"7","key":"8317_CR12","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","volume":"78","author":"S Sabbagh","year":"2019","unstructured":"Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG, Mammen AL, Childhood Myositis Heterogeneity Collaborative Study G (2019) Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis 78(7):988\u2013995. https:\/\/doi.org\/10.1136\/annrheumdis-2018-215004","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"8317_CR13","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1093\/rheumatology\/keaa786","volume":"60","author":"A Xu","year":"2021","unstructured":"Xu A, Ye Y, Fu Q, Lian X, Chen S, Guo Q, Lu LJ, Dai M, Lv X, Bao C (2021) Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease. Rheumatology (Oxford) 60(7):3343\u20133351. https:\/\/doi.org\/10.1093\/rheumatology\/keaa786","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"8317_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3899\/jrheum.220139","volume":"50","author":"C Lv","year":"2023","unstructured":"Lv C, You H, Xu L, Wang L, Yuan F, Li J, Wu M, Zhou S, Da Z, Qian J, Wei H, Yan W, Zhou L, Wang Y, Yin S, Zhou D, Wu J, Lu Y, Su D, Liu Z, Liu L, Ma L, Xu X, Zang Y, Liu H, Ren T, Wang F, Zhang M, Tan W (2023) Coexistence of anti-Ro52 antibodies in anti-MDA5 antibody-positive dermatomyositis is highly associated with rapidly progressive interstitial lung disease and mortality risk. J Rheumatol 50(2):219\u2013226. https:\/\/doi.org\/10.3899\/jrheum.220139","journal-title":"J Rheumatol"},{"issue":"1","key":"8317_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03141-4","volume":"25","author":"V Hamberg","year":"2023","unstructured":"Hamberg V, Sohrabian A, Volkmann ER, Wildt M, Lofdahl A, Wuttge DM, Hesselstrand R, Dellgren G, Westergren-Thorsson G, Ronnelid J, Andreasson K (2023) Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study. Arthritis Res Ther 25(1):162. https:\/\/doi.org\/10.1186\/s13075-023-03141-4","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"8317_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12016-007-8013-6","volume":"34","author":"R Maya","year":"2008","unstructured":"Maya R, Gershwin ME, Shoenfeld Y (2008) Hepatitis B virus (HBV) and autoimmune disease. Clin Rev Allergy Immunol 34(1):85\u2013102. https:\/\/doi.org\/10.1007\/s12016-007-8013-6","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9","key":"8317_CR17","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, M\u00e9nard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsk\u00fd J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569\u20132581. https:\/\/doi.org\/10.1002\/art.27584","journal-title":"Arthritis Rheum"},{"issue":"9","key":"8317_CR18","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstr\u00f8m K, Massarotti E, McCune J, Ruiz-Irastorza R, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirj\u00e1k L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kum\u00e1novics K, Mariette X, Padjen J, Pego-Reigosa JM, Romero-Diaz J, R\u00faa-Figueroa Fern\u00e1ndez \u00cd, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, D\u00f6rner T, Johnson SR (2019) 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 71(9):1400\u20131412. https:\/\/doi.org\/10.1002\/art.40930","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"8317_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","volume":"76","author":"CH Shiboski","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, Mariette X (2017) 2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Annals of the Rheumatic Diseases 76(1):9\u201316. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210571","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"12","key":"8317_CR20","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dank\u00f3 K, Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O\u2019Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG (2017) 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76(12):1955\u20131964. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211468","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"8317_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/annrheumdis-2021-221795","volume":"81","author":"JC Robson","year":"2022","unstructured":"Robson JC, Grayson PC, Ponte C, Suppiah R, Craven A, Judge A, Khalid S, Hutchings A, Watts RA, Merkel PA, Luqmani RA (2022) 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis 81(3):315\u2013320. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221795","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"8317_CR22","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, M\u00fcller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Ellen Csuka M, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 72(11):1747. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204424","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"8317_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/bf01451046","volume":"17","author":"MG Danieli","year":"1998","unstructured":"Danieli MG, Fraticelli P, Salvi A, Gabrielli A, Danieli G (1998) Undifferentiated connective tissue disease: natural history and evolution into definite CTD assessed in 84 patients initially diagnosed as early UCTD. Clin Rheumatol 17(3):195\u2013201. https:\/\/doi.org\/10.1007\/bf01451046","journal-title":"Clin Rheumatol"},{"issue":"11","key":"8317_CR24","first-page":"2345","volume":"29","author":"M Mosca","year":"2002","unstructured":"Mosca M, Neri R, Bencivelli W, Tavoni A, Bombardieri S (2002) Undifferentiated connective tissue disease: analysis of 83 patients with a minimum followup of 5 years. J Rheumatol 29(11):2345\u20132349","journal-title":"J Rheumatol"},{"issue":"3","key":"8317_CR25","first-page":"313","volume":"21","author":"E Bodolay","year":"2003","unstructured":"Bodolay E, Csiki Z, Szekanecz Z, Ben T, Kiss E, Zeher M, Sz\u00fccs G, Dank\u00f3 K, Szegedi G (2003) Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol 21(3):313\u2013320","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"8317_CR26","first-page":"213","volume":"15","author":"A Kansu","year":"2004","unstructured":"Kansu A, Kulo\u011flu Z, Demir\u00e7eken F, Girgin N (2004) Autoantibodies in children with chronic hepatitis B infection and the influence of interferon alpha. Turk J Gastroenterol 15(4):213\u2013218","journal-title":"Turk J Gastroenterol"},{"issue":"2","key":"8317_CR27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/jmv.1890340212","volume":"34","author":"G Fattovich","year":"1991","unstructured":"Fattovich G, Betterle C, Brollo L, Pedini B, Giustina G, Realdi G, Alberti A, Ruol A (1991) Autoantibodies during alpha-interferon therapy for chronic hepatitis B. J Med Virol 34(2):132\u2013135. https:\/\/doi.org\/10.1002\/jmv.1890340212","journal-title":"J Med Virol"},{"issue":"12","key":"8317_CR28","first-page":"CR1","volume":"8","author":"I Kacprzak-Bergman","year":"2002","unstructured":"Kacprzak-Bergman I, Zaleska I, Gruszka J, Kuchar E (2002) Autoantibodies in children with chronic hepatitis B undergoing interferon therapy. Med Sci Monit 8(12):CR1\u2013824","journal-title":"Med Sci Monit"},{"key":"8317_CR29","doi-asserted-by":"publisher","first-page":"16047","DOI":"10.1038\/nrdp.2016.47","volume":"2","author":"P Brito-Zeron","year":"2016","unstructured":"Brito-Zeron P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, Sivils K, Theander E, Tzioufas A, Ramos-Casals M (2016) Sjogren syndrome. Nat Rev Dis Primers 2:16047. https:\/\/doi.org\/10.1038\/nrdp.2016.47","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"8317_CR30","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1073\/pnas.81.7.1996","volume":"81","author":"SL Wolin","year":"1984","unstructured":"Wolin SL, Steitz JA (1984) The Ro small cytoplasmic ribonucleoproteins: identification of the antigenic protein and its binding site on the Ro RNAs. Proc Natl Acad Sci U S A 81(7):1996\u20132000. https:\/\/doi.org\/10.1073\/pnas.81.7.1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"8317_CR31","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1084\/jem.167.5.1560","volume":"167","author":"E Ben-Chetrit","year":"1988","unstructured":"Ben-Chetrit E, Chan EK, Sullivan KF, Tan EM (1988) A 52-kD protein is a novel component of the SS-A\/Ro antigenic particle. J Exp Med 167(5):1560\u20131571. https:\/\/doi.org\/10.1084\/jem.167.5.1560","journal-title":"J Exp Med"},{"issue":"1\u20132","key":"8317_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaut.2012.01.014","volume":"39","author":"V Oke","year":"2012","unstructured":"Oke V, Wahren-Herlenius M (2012) The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J Autoimmun 39(1\u20132):77\u201382. https:\/\/doi.org\/10.1016\/j.jaut.2012.01.014","journal-title":"J Autoimmun"},{"issue":"6","key":"8317_CR33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.autrev.2005.10.004","volume":"5","author":"SL Wolin","year":"2006","unstructured":"Wolin SL, Reinisch KM (2006) The Ro 60 kDa autoantigen comes into focus: interpreting epitope mapping experiments on the basis of structure. Autoimmun Rev 5(6):367\u2013372. https:\/\/doi.org\/10.1016\/j.autrev.2005.10.004","journal-title":"Autoimmun Rev"},{"key":"8317_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00444","volume":"10","author":"A Robbins","year":"2019","unstructured":"Robbins A, Hentzien M, Toquet S, Didier K, Servettaz A, Pham BN, Giusti D (2019) Diagnostic utility of separate anti-Ro60 and anti-Ro52\/TRIM21 antibody detection in autoimmune diseases. Front Immunol 10:444. https:\/\/doi.org\/10.3389\/fimmu.2019.00444","journal-title":"Front Immunol"},{"issue":"2","key":"8317_CR35","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/BOR.0b013e32835c7e32","volume":"25","author":"M-L Eloranta","year":"2013","unstructured":"Eloranta M-L, R\u00f6nnblom L (2013) The interferon signature in autoimmune diseases. Curr Opin Rheumatol 25(2):248\u2013253. https:\/\/doi.org\/10.1097\/BOR.0b013e32835c7e32","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"8317_CR36","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12016-020-08798-2","volume":"59","author":"J Jiang","year":"2020","unstructured":"Jiang J, Zhao M, Chang C, Wu H, Lu Q (2020) Type I interferons in the pathogenesis and treatment of autoimmune diseases. Clin Rev Allergy Immunol 59(2):248\u2013272. https:\/\/doi.org\/10.1007\/s12016-020-08798-2","journal-title":"Clin Rev Allergy Immunol"},{"key":"8317_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2023.100204","volume":"7","author":"J-M Anaya","year":"2023","unstructured":"Anaya J-M, Beltr\u00e1n S (2023) The autoimmune tautology revisited. Journal of Translational Autoimmunity 7:100204. https:\/\/doi.org\/10.1016\/j.jtauto.2023.100204","journal-title":"Journal of Translational Autoimmunity"},{"issue":"5","key":"8317_CR38","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/art.42789","volume":"76","author":"E Bettacchioli","year":"2024","unstructured":"Bettacchioli E, Saraux A, Tison A, Cornec D, Dueymes M, Foulquier N, Hillion S, Roguedas-Contios AM, Benyoussef AA, Alarcon-Riquelme ME, Pers JO, Devauchelle-Pensec V, Consortium PC, Consortium PS (2024) Association of combined anti-Ro52\/TRIM21 and anti-Ro60\/SSA antibodies with increased Sjogren disease severity through interferon pathway activation. Arthritis Rheumatol 76(5):751\u2013762. https:\/\/doi.org\/10.1002\/art.42789","journal-title":"Arthritis Rheumatol"},{"key":"8317_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02049","volume":"10","author":"S Foss","year":"2019","unstructured":"Foss S, Bottermann M, Jonsson A, Sandlie I, James LC, Andersen JT (2019) TRIM21-from intracellular immunity to therapy. Front Immunol 10:2049. https:\/\/doi.org\/10.3389\/fimmu.2019.02049","journal-title":"Front Immunol"},{"key":"8317_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2023.104776","volume":"393\u2013394","author":"E Holwek","year":"2023","unstructured":"Holwek E, Opinc-Rosiak A, Sarnik J, Makowska J (2023) Ro52\/TRIM21 - from host defense to autoimmunity. Cell Immunol 393\u2013394:104776. https:\/\/doi.org\/10.1016\/j.cellimm.2023.104776","journal-title":"Cell Immunol"},{"issue":"16","key":"8317_CR41","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1056\/NEJMoa021933","volume":"349","author":"MR Arbuckle","year":"2003","unstructured":"Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349(16):1526\u20131533. https:\/\/doi.org\/10.1056\/NEJMoa021933","journal-title":"N Engl J Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08317-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08317-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08317-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:04:34Z","timestamp":1789545874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08317-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8317"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08317-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the First Affiliated Hospital of Xiamen University ethics committee (2024 Scientific Research Ethics Approval (150)).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"At the time of admission, all patients provided written informed consent, permitting the use of their clinical data and biological samples for scientific research purposes.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":3,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients or the public were not involved in the design, conduct, reporting, or dissemination plans of our research.","order":4,"name":"Ethics","label":"Patient and public involvement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}